<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16718">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020109</url>
  </required_header>
  <id_info>
    <org_study_id>13-11-05/06-extern-6295</org_study_id>
    <nct_id>NCT02020109</nct_id>
  </id_info>
  <brief_title>Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia</brief_title>
  <official_title>Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective evaluation on the effect of splenic irradiation on clinical and hematological
      response and toxicity in patients with chronic lymphatic leukaemia (CLL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with CLL treated with splenic irradiation in Maastro Clinic,
      Maastricht, The Netherlands, Maxima Medisch Centrum Veldhoven/Catharina hospital, Eindhoven,
      The Netherlands and Modena hospital, Modena, Italy. Data will be collected from patient
      records in an uniform database. Data will include demographic data, CLL stadium (RAI and
      Binet) at diagnosis and at the time of irradiation treatment, clinical data at diagnosis
      (haematology), splenic irradiation data, follow-up data such as date of progression or death
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Clinical and haematological response</measure>
    <time_frame>13 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical and haematological response measured by number of leucocytes and thrombocytes during and after irradiation. Hemoglobin and size of spleen during and after irradiation in the time period 2000 tot 2013</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of chronic Lymphatic leukaemia</measure>
    <time_frame>13 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression of chronic Lymphatic leukaemia after irradiation in the time period 2000 tot 2013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>13 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be followed from the time of splenic irradiation to death in the time period of 2000 tot 2013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of splenic irradiation</measure>
    <time_frame>13 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Toxicity of splenic irradiation during and after irradiation measured by evaluating clinical toxicity based on the CTCAE version 3.0 during and after irradiation (2000 to 2013)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Chronic Lymphatic</condition>
  <arm_group>
    <arm_group_label>Patients with Chronic Lymphatic Leukemia</arm_group_label>
    <description>Patients with Chronic Lymphatic Leukemia treated with splenic irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>splenic irradiation</intervention_name>
    <arm_group_label>Patients with Chronic Lymphatic Leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphatic leukaemia (CLL).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with chronic lymphatic leukaemia.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Borger, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Borger, Dr.</last_name>
    <email>jacques.borger@maastro.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Borger, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Borger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roel Schlijper</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
